| SSc patients (n = 93) . | . |
|---|---|
| Demographic and clinical characteristics | |
| Female, n (%) | 80 (86.0) |
| Age (years), mean (s.d.) | 48.5 (10.3) |
| dcSSc, n (%) | 48 (52) |
| lcSSc, n (%) | 45 (48) |
| Autoantibodies | |
| Anti-Scl70 positive, n (%) | 29 (31) |
| Anti-centromere positivity, n (%) | 27 (29) |
| Medication | |
| ACE inhibitors/ARBs, n (%) | 42 (45) |
| Calcium-channel blockers, n (%) | 76 (82) |
| PAH medication, n (%) | 28 (30) |
| β-blockers, n (%) | 26 (28) |
| Associated diseases | |
| Systemic arterial hypertension, n (%) | 23 (25) |
| Dyslipidaemia, n (%) | 21 (23) |
| DM, n (%) | 5 (5) |
| Anaemia, n (%) | 22 (24) |
| Thyroid dysfunction, n (%) | 11 (12) |
| SSc patients (n = 93) . | . |
|---|---|
| Demographic and clinical characteristics | |
| Female, n (%) | 80 (86.0) |
| Age (years), mean (s.d.) | 48.5 (10.3) |
| dcSSc, n (%) | 48 (52) |
| lcSSc, n (%) | 45 (48) |
| Autoantibodies | |
| Anti-Scl70 positive, n (%) | 29 (31) |
| Anti-centromere positivity, n (%) | 27 (29) |
| Medication | |
| ACE inhibitors/ARBs, n (%) | 42 (45) |
| Calcium-channel blockers, n (%) | 76 (82) |
| PAH medication, n (%) | 28 (30) |
| β-blockers, n (%) | 26 (28) |
| Associated diseases | |
| Systemic arterial hypertension, n (%) | 23 (25) |
| Dyslipidaemia, n (%) | 21 (23) |
| DM, n (%) | 5 (5) |
| Anaemia, n (%) | 22 (24) |
| Thyroid dysfunction, n (%) | 11 (12) |
ACE: angiotensin-converting enzyme; ARBs: angiotensin-receptor blockers; DM: diabetes mellitus; PAH: pulmonary arterial hypertension.
| SSc patients (n = 93) . | . |
|---|---|
| Demographic and clinical characteristics | |
| Female, n (%) | 80 (86.0) |
| Age (years), mean (s.d.) | 48.5 (10.3) |
| dcSSc, n (%) | 48 (52) |
| lcSSc, n (%) | 45 (48) |
| Autoantibodies | |
| Anti-Scl70 positive, n (%) | 29 (31) |
| Anti-centromere positivity, n (%) | 27 (29) |
| Medication | |
| ACE inhibitors/ARBs, n (%) | 42 (45) |
| Calcium-channel blockers, n (%) | 76 (82) |
| PAH medication, n (%) | 28 (30) |
| β-blockers, n (%) | 26 (28) |
| Associated diseases | |
| Systemic arterial hypertension, n (%) | 23 (25) |
| Dyslipidaemia, n (%) | 21 (23) |
| DM, n (%) | 5 (5) |
| Anaemia, n (%) | 22 (24) |
| Thyroid dysfunction, n (%) | 11 (12) |
| SSc patients (n = 93) . | . |
|---|---|
| Demographic and clinical characteristics | |
| Female, n (%) | 80 (86.0) |
| Age (years), mean (s.d.) | 48.5 (10.3) |
| dcSSc, n (%) | 48 (52) |
| lcSSc, n (%) | 45 (48) |
| Autoantibodies | |
| Anti-Scl70 positive, n (%) | 29 (31) |
| Anti-centromere positivity, n (%) | 27 (29) |
| Medication | |
| ACE inhibitors/ARBs, n (%) | 42 (45) |
| Calcium-channel blockers, n (%) | 76 (82) |
| PAH medication, n (%) | 28 (30) |
| β-blockers, n (%) | 26 (28) |
| Associated diseases | |
| Systemic arterial hypertension, n (%) | 23 (25) |
| Dyslipidaemia, n (%) | 21 (23) |
| DM, n (%) | 5 (5) |
| Anaemia, n (%) | 22 (24) |
| Thyroid dysfunction, n (%) | 11 (12) |
ACE: angiotensin-converting enzyme; ARBs: angiotensin-receptor blockers; DM: diabetes mellitus; PAH: pulmonary arterial hypertension.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
